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Abstract
Background: Microarray analyses allow the identification and assessment of molecular signatures
in whole tissues undergoing pathological processes. To better understand cerebral malaria
pathogenesis, we investigated intra-cerebral gene-expression profiles in well-defined genetically
cerebral malaria-resistant (CM-R) and CM-susceptible (CM-S) mice, upon infection by Plasmodium
berghei ANKA (PbA). We investigated mouse transcriptional responses at early and late stages of
infection by use of cDNA microarrays.
Results: Through a rigorous statistical approach with multiple testing corrections, we showed that
PbA significantly altered brain gene expression in CM-R (BALB/c), and in CM-S (CBA/J and C57BL/
6) mice, and that 327 genes discriminated between early and late infection stages, between mouse
strains, and between CM-R and CM-S mice. We further identified 104, 56, 84 genes with significant
differential expression between CM-R and CM-S mice on days 2, 5, and 7 respectively. The analysis
of their functional annotation indicates that genes involved in metabolic energy pathways, the
inflammatory response, and the neuroprotection/neurotoxicity balance play a major role in
cerebral malaria pathogenesis. In addition, our data suggest that cerebral malaria and Alzheimer's
disease may share some common mechanisms of pathogenesis, as illustrated by the accumulation
of β-amyloid proteins in brains of CM-S mice, but not of CM-R mice.
Conclusion: Our microarray analysis highlighted marked changes in several molecular pathways
in CM-S compared to CM-R mice, particularly at early stages of infection. This study revealed some
promising areas for exploration that may both provide new insight into the knowledge of CM
pathogenesis and the development of novel therapeutic strategies.
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Background
Malaria is a disease affecting millions of people world-
wide. Cerebral malaria (CM) is one of the most severe
complications and is a major cause of death. Both host
and parasite genetic factors play important roles in the
outcome of malaria infection. Epidemiological data, can-
didate gene studies, and genetic linkage studies clearly
support the existence of a genetic contribution to suscep-
tibility to human malaria [1]. In parallel with human
studies, malaria susceptibility genes have been mapped in
mouse models, and the role of some genes has been dem-
onstrated [2]. It is clear, however, that a number of
malaria susceptibility genes remain to be identified. These
include genes, whose expression is likely deregulated
upon malaria infection.
Transcriptional profiling may provide new tools for iden-
tifying the key genes that govern host responses against
pathogens. Recently, several reports have described gene
expression changes that accompany the host response
against Plasmodium spp. Microarrays have been analyzed
from mice [3-5], rhesus monkey [6] and humans [7],
upon infection by Plasmodium spp  A parallel can be
observed in the regulation of genes involved in immune
responses, glycolysis, and erythropoiesis. These data sug-
gested that variation in host gene expression may be asso-
ciated with resistance or susceptibility to malaria.
Recently, we investigated brain gene expression patterns
in well-defined genetically CM-resistant (CM-R) and CM-
susceptible mice (CM-S) by use of cDNA microarrray [8].
We identified a set of genes that perfectly discriminates
between CM-R and CM-S mice at the time of CM onset.
This indicates that gene expression analysis using microar-
ray tools may be useful for the identification of candidate
genes that are potentially responsible for resistance or sus-
ceptibility to CM. Nevertheless, an important issue was to
identify genes whose expression differ between CM-R and
CM-S mice before the time of CM onset to identify early
events that may participate in malaria pathogenesis. In
this report, we present an analysis of genes differentially
expressed in brains from CM-R and CM-S mice prior to
infection, and at the early and late stages of infection with
Plasmodium berghei ANKA (PbA). Data analysis reveals
that molecules belonging to several biological processes
were preferentially and differentially expressed between
CM-R and CM-S mice, and that a number of gene expres-
sion changes occurred at the early and late stages of infec-
tion. Herein, we discuss new working hypotheses on this
basis.
Results
Identification of genes regulated in brains by PbA infection
The ANOVA of microarray data revealed significant gene
expression changes over the course of infection in BALB/c
(n = 25) mice, CBA/J mice (n = 16), and in C57BL/6 mice
(n = 20). We calculated empirical P values for each gene,
and we considered P < 0.05 significant. On this basis, we
selected 174, 210, and 342 genes for BALB/c mice, CBA/J
mice, and C57BL/6 mice, respectively.
To further compare uninfected mice with infected mice,
we performed a Welch t test and we applied a Bonferroni
correction to account for multiple tests performed (Figure
1). Figure 2 shows the number of genes whose expression
was significantly altered by PbA infection. The mouse
strains displayed various patterns. Strikingly, the number
of genes that showed significant expression changes was
higher in C57BL/6 mice than in CBA/J mice on day 2 post-
infection with PbA (Figure 2A). The number of genes that
showed significant expression changes in CBA/J mice
gradually increased during infection. In contrast, the
number of genes that showed significant expression
changes in both C57BL/6 mice and BALB/c mice on day 2
was similar to the number of genes identified on day 7; it
was, nevertheless, lower on day 5 than on days 2 and 7. As
shown in Figure 2, most of the genes identified in C57BL/
6 mice (Figure 2B) and in CBA/J mice (Figure 2C) were
under-expressed, while most of the genes identified in
BALB/c mice (Figure 2D) were over-expressed.
A Venn diagram summarizes the number of overlapping
genes with significant differential expression at different
time points (Figure 3). Most of the genes identified on day
Schematic outline of data analysis Figure 1
Schematic outline of data analysis. HCL: hierarchical 
clustering. a Brain gene expression prior to infection was 
compared with brain gene expression on days 2, 5 and 7. b 
Brain gene expression in CM-R mice was compared with that 
in CM-S mice at each time point. As represented by dashed 
arrows, we considered the whole data set (n = 2012 genes) 
to carry out multiple testing correction.
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2 were no longer identified on day 7 in C57BL/6 mice and
in BALB/c mice. As shown in Figure 3A–B and 3E–F, 42 of
53 and 31 of 36 genes with differential expression on day
2 did not show differential expression on days 5 and 7 in
C57BL/6 and BALB/c mice, respectively. In contrast, 10 of
14 genes regulated by PbA infection on day 2 were also
regulated on days 5 and 7 in CBA/J mice (Figure 3C–D),
indicating that C57BL/6 mice and CBA/J mice partly differ
in their transcriptional response over the course of infec-
tion.
Microarray analysis discriminates between CM-R and CM-
S mice according to the time after infection
We searched for genes showing differential expression
between mouse strains before infection. The ANOVA
identified 125 genes without multiple test correction
(data not shown), and 7 genes with Bonferroni multiple
Overlapping genes with significant differential expression at  different time points during PbA infection Figure 3
Overlapping genes with significant differential 
expression at different time points during PbA infec-
tion. This Venn diagrams show the number of overlapping 
genes with significant expression changes on days 2, 5, and 7 
post-infection with PbA, for C57BL/6 mice (A and B), CBA/J 
mice (C and D) and BALB/c mice (E and F). Genes that are 
either induced or suppressed by infection are distinguished 
for each strain: the number of genes induced is shown in A, 
C, and E, while the number of genes suppressed is shown in 
B, D, and F.
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Distribution of genes regulated by PbA infection according to  the time of infection Figure 2
Distribution of genes regulated by PbA infection 
according to the time of infection. The genes whose 
expression was significantly altered by PbA infection were 
identified by using pair-wise Welch t tests with a Bonferroni 
correction.A. The number of genes with significant changes 
is shown at each time point for each mouse strain. B, C and 
D. The number of genes significantly up- (positive values) and 
down-regulated (negative values) is shown at each time point 
for each mouse strain.
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test correction at the level of 5%: 1700023B02Rik, Acot8,
Gpd2, Sec11c, Ngly1, Zfp346 and Tln2. These results
revealed a minor natural variation in gene expression
between mouse strains. Nevertheless, we took into
account this natural variation in further analyses to search
for transcriptional changes. Thus, the individual gene
expression level in infected mice was adjusted for the gene
expression level in uninfected mice for each mouse strain.
To focus on transcriptional changes associated with resist-
ance or susceptibility, we searched for a set of genes that
discriminated between CM-R mice (BALB/c) and CM-S
mice (C57BL/6 and CBA/J). To this end, we used the
multi-class Significant Analysis of Microarrays (SAM) pro-
cedure, and we applied a false discovery rate of 0% (Figure
1). The analysis yielded a set of 327 genes [see Additional
file 1], which was used to perform unsupervised hierarchi-
cal clustering (Figure 4A). Interestingly, the expression of
several genes was induced in CM-R mice or suppressed in
CM-S mice as a result of infection, while the expression of
other genes was suppressed in CM-R mice and induced in
CM-S mice [see Additional file 1]. This led to successfully
classify CM-R and CM-S mice according to the time after
infection (Figure 4B) and to determine five clusters (Fig-
ure 4A). Clusters A and C fully grouped CM-R mice
(BALB/c) versus CM-S mice (C57BL/6 and CBA/J) what-
ever the time after infection. Genes of cluster A were over-
expressed in CM-S mice compared to CM-R mice, while
genes of cluster C were under-expressed in CM-S mice
compared to CM-R mice. Clusters B and D also grouped
CM-R mice versus CM-S mice. Nevertheless, clusters B and
D discriminated between C57BL/6 and CBA/J mice, indi-
cating differential gene expression between the two CM-S
strains at early time points of infection. Genes of clusters
B and D were over-expressed in CBA/J mice on day 2 post-
infection compared to C57BL/6 mice, and in C57BL/6 on
days 2 and 5 post-infection compared to CBA/J mice,
respectively. At late stage of infection, genes of clusters B
and D showed similar gene expression between the two
CM-S strains, and were under-expressed in CM-S mice
compared to CM-R mice. Cluster E discriminated mice at
early and late stage of infection. Nevertheless, genes of
cluster E were over-expressed in CM-S mice compared to
CM-R mice indicating an interval between the response of
CM-S and the response of CM-R mice.
To analyze functional annotations related to CM, we
sought biological process Gene Ontology (GO) terms and
KEGG pathways for the 327 genes that discriminated
between CM-R mice (BALB/c) and CM-S mice (C57BL/6
and CBA/J). The analysis of biological process GO terms
of gene clusters showed an over-representation of some
GO terms. In particular, the GO terms related to the
"defense response" category, such as the "immune
response" or the "inflammatory response" GO terms were
strongly over-represented in cluster E (Table 1). Similarly,
most of the genes grouped in cluster E were found to be
involved in KEGG pathways related to immune responses,
such as "cytokine-cytokine receptor interaction" or "natu-
ral killer cell mediated cytotoxicity". The analysis of other
clusters did not reveal, however, a strong over-representa-
tion of particular GO terms, suggesting that these clusters
were heterogeneous. In particular, clusters B and C con-
tained 38 and 207 genes with heterogeneous GO catego-
ries. This was further supported by the analysis of KEGG
pathways, which pointed out a number of different path-
ways, such as metabolic energy pathways ("glycolysis/glu-
coneogenesis" and "oxidative phosphorylation"),
immune responses ("cytokine-cytokine receptor interac-
tion" and "antigen processing and presentation"), hae-
matopoiesis, ("hematopoietic cell lineage"), cytoskeleton
pathways ("regulation of active cytoskeleton"), or path-
ways related to brain function ("neurodegenerative disor-
ders" and "axon guidance") (Figure 5).
We specifically searched for genes with significant differ-
ential expression between CM-R and CM-S mice. Thus, we
used the Welch t test to compare BALB/c mice (CM-R
mice) on the one hand and CBA/J mice and C57BL/6 mice
(CM-S mice) on the other hand (Figure 1). We tested the
327 genes identified by the SAM multi-class procedure,
but we considered the whole data set (n = 2012 genes) to
carry out multiple testing correction. Among the 327
genes, 177 genes were further found to be differentially
expressed between CM-R mice and CM-S mice (Table 2).
Among the 177 genes, 104, 56, and 84 genes showed sig-
nificant differential expression on days 2, 5, and 7, respec-
tively, and 11, 17, 138, and 11 were grouped in clusters A,
B, C and E, respectively. The number of co-occurring genes
with differential expression between CM-R and CM-S
mice detected at different times is displayed in Figure 6.
Eighteen of 177 genes were up-regulated in CM-S mice
compared to CM-R mice, while 158 of 177 genes were up-
regulated in CM-R mice compared to CM-S mice. Only
one gene showed a complicated picture: Fyco1 was down-
regulated in CBA/J and C57BL/6 mice (CM-S mice) mice
on day 2, and in CBA/J mice on day 5, while it was up-reg-
ulated in C57BL/6 mice on day 5. Table 3 show the most
represented KEGG pathways, which included pathways
related to metabolism, erythropoiesis, immune responses,
neuronal development, and neurodegenerative disorders.
We further analyzed the expression of genes involved in
neuronal development or in neurodegenerative disorders
using immunochemistry. Thus, we studied the expression
of reelin (Reln), which is involved in neurogenesis, and
we searched for the presence of β-amyloid protein, which
is involved in Alzheimer's disease. We detected RELN only
in brains of BALB/c mice at days 5 and 7, while we showedBMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
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Hierarchical classification of mouse-strain-specific and CM-R/CM-S genes according to the time of infection Figure 4
Hierarchical classification of mouse-strain-specific and CM-R/CM-S genes according to the time of infection. A. 
Hierarchical clustering of the 58 brain tissue samples, using expression levels of 327 significant genes differentially expressed 
between the mouse strains at early and late stages of infection. This set of genes was extracted from the full data set (n = 2012) 
by use of a SAM procedure and a false discovery rate of 0%. Each row represents a gene and each column represents a sample. 
Red and green indicate expression levels above and below the median, respectively. Grey indicates missing data. Dendograms 
of samples (above matrix) and genes (to the left of matrix) represent overall similarities in gene expression profiles. B. Dendo-
gram of samples representing the results of the same global hierarchical clustering applied to the 58 brain tissue samples. Clus-
tering of technical replicates (CBA/J-5, C57BL6-20 and BALB/c-13) is shown: the samples taken from a CBA/J mouse on day 2, 
a C57L/6 mouse on day 7, and a BALB/c mouse on day 7 were run on 5, 2, and 2 microarrays, respectively. Samples taken from 
mice on days 2, 5, 7, 9, and 15 post-infection are coded D2, D5, D7, D9, and D15, respectively.
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the presence of β-amyloid only in brains of CBA/J and
C57BL/6 mice at days 5 and 7 (Table 4).
Overall, our gene expression analysis revealed marked
changes in metabolic energy pathways, the inflammatory
response, and pathways related to neurogenesis and neu-
rodegenerative disorders in CM-S mice versus CM-R mice.
Discussion
In the present study, we have searched for genes and phys-
iological pathways potentially involved in CM. To this
aim, we performed a longitudinal analysis of differentially
expressed genes in brains from well-defined genetically
CM-R (BALB/c) and CM-S (C57BL/6, and CBA/J) mice at
early and late stages of infection. The present study shows
that PbA strongly altered gene expression in these mice. In
particular, gene expression was deeply altered at the time
of CM onset, confirming our previous study [8]. Here, we
show that a number of genes were over-expressed in CM-
R mice at the early stage of infection, suggesting that CM-
R mice mount an early protective transcriptional
response. In this way, we found an association of resist-
ance to CM with an increase in the expression of a number
of genes on day 2 post-infection (Figure 4 and Table 2). In
contrast, a number of genes were found to be under-
expressed in C57BL/6 mice at the early stage of infection,
while few genes were found to be regulated in CBA/J mice
at the same time (Figure 2). Also, CBA/J mice appeared to
mount a gradual response that may be involved in CM
pathogenesis, while C57BL/6 mice may mount two waves
of transcriptional responses both of them potentially
implicated in malaria pathogenesis. These observations
are consistent with other reports suggesting that CM medi-
ators partly differ between C57BL/6 and CBA/J mice [8-
10]. Nevertheless, both CBA/J and C57BL/6 mice showed
a pronounced up-regulation of genes involved in either
interferon-associated response or in glycolysis at the late
stage, and a down-regulation of genes involved in erythro-
poiesis both at early and late stages, as previously
described [3].
To identify genes with significant transcriptional changes
associated with CM, we performed, on the whole data set,
a multi-class SAM procedure with a very stringent false
discovery rate followed by a Welch t test with a Bonferroni
correction. In other words, we applied a two-filtering pro-
cedure to decrease the number of "false positive" genes.
To account for natural variation between mouse strains,
we adjusted gene expression level in infected mice for
gene expression level in uninfected mice. Thus, we identi-
View of biological functional annotation repartition of the  genes grouped in clusters B and C Figure 5
View of biological functional annotation repartition 
of the genes grouped in clusters B and C. The KEGG 
pathways, in which the genes were known to be involved, are 
shown. Of the 245 genes of the clusters B and C, 80 were 
annotated. We represented only the KEGG pathways that 
contained at least three genes.
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ECM-receptor interaction 
Leukocyte transendothelial migration
Jak-STAT signaling pathway
Tryptophan metabolism
Fructose and mannose metabolism
Neurodegenerative Disorders
Valine, leucine and isoleucine degradation
Insulin signaling pathway
Percentage of genes
0123456789 1 0
Table 1: Enrichment of the 327 genes differentially expresseda in 
Gene Ontology terms
Cluster, GO term Fisher exact testb
Cluster A
Defense responsec 0.043
Cluster B
... ...
Cluster C
Positive regulation of cell activationc 0.0024
Positive regulation of lymphocyte 0.0024
activationc
Positive regulation of cellular 0.006
physiological processc
Regulation of phosphorylationc 0.008
Cell death 0.013
Positive regulation of immune response 0.015
Positive regulation of cellular 0.036
biosynthesis
Cytokines and inflammatory response 0.049
Cluster D
... ...
Cluster E
Defense response 0.0000001 d
Immune response 0.000004d
Response to pest/pathogen/parasite 0.0000051d
Inflammatory response 0.0027
Response to stress 0.0028
Response to wounding 0.003
Chemotaxis 0.0054
Response to external stimulus 0.011
a This set of genes was extracted from the full data set (n = 2012) by 
use of a SAM procedure and a false discovery rate of 0%.
b Significant results with a Fischer exact test (P < 0.05).
c GO terms that were also over-represented in the set of 177 
significant CM genes.
d Significant results with the Benjamini multi-testing correction (P < 
0.05).BMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
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Table 2: CM-specific genes obtained by use of the Welch t test and a Bonferroni correction
IDa Cluster Symbolb Name Chrc Welch t testd
BG083931 A Slc25a11 Solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11 11 D2 ... ...
718084 A Dfy Duffy blood group 1 D2 ... ...
BG064714 A Slc3a2 Solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 19 D2 ... ...
573549 A Mrps34 Mitochondrial ribosomal protein S34 17 D2 D5 ...
641184 A Cdc37l1 Cell division cycle 37 homolog (S. cerevisiae)-like 19 D2 D5e ...
641058 A Nfkbia Nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha 12 ... D5 D7
BG086014 A Hmgn1 High mobility group nucleosomal binding domain 1 16 D2 D5 ...
639606 A E030041M21Rik RIKEN cDNA E030041M21 gene 10 D2f D5 ...
636468 A Epb4.1l3 Erythrocyte protein band 4.1-like 3 17 ... D5 ...
BG084377 A Stat3 Signal transducer and activator of transcription 3 11 D2 ... ...
582660 A Tagap1 T-cell activation GTPase activating protein 1 17 D2 D5 D7
573243 B Ddi2 DNA-damage inducible protein 2 4 ... D5 ...
BG071164 B 2310008M10Rik RIKEN cDNA 2310008M10 gene 3 D2 ... D7
BG070859 B Nipbl Nipped-B homolog (Drosophila) 15 ... D5e D7
639002 B Mlx MAX-like protein X 11 D2 D5 D7
BG072955 BM y o 5 a M y o s i n  V a 9 ... ... D7
575433 B Ptger1 Prostaglandin E receptor 1 (subtype EP1), 42 kD 8 ... ... D7
BG087138 B Itsn2 Intersectin 2 12 D2 ... D7
BG078795 B Hspa5 Heat shock 70 kD protein 5 (glucose-regulated protein) 2 ... ... D7
BG064608 BC a l r C a l r e t i c u l i n 8 ... ... D7
BG087169 B P4hb Protein disulfide isomerase associated 6 12 ... ... D7
764825 BR e l n R e e l i n 5 D2 ... ...
1263789 B Cxcl12 Chemokine (C-X-C motif) ligand 12 6 D2 ... ...
441212 B Atp6v1g2 ATPase, H+ transporting, lysosomal 13 kD, V1 subunit G isoform 2 17 D2 ... ...
577991 B Zdhhc6 Zinc finger, DHHC domain containing 6 19 ... D5 ...
1263101 B Hmgcs1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 13 ... D5 ...
573257 B Pcgf3 Polycomb group ring finger 3 5 ... ... D7
436894 B Fabp7 Fatty acid binding protein 7, brain 10 ... ... D7
BG076809 C Rps18 Ribosomal protein S18 17 D2 ... ...
BG085025 C Dab1 Disabled homolog 1 (Drosophila) 4 ... D5 ...
718873 C S100a10 S100 calcium binding protein A10 (calpactin) 3 D2 D5 ...
576647 C Chchd1 Coiled-coil-helix-coiled-coil-helix domain containing 1 14 D2 D5 ...
BG063799 C Ak3l1 Adenylate kinase 3 alpha-like 1 4 ... ... D7
BG077012 C Cdc6 Cell division cycle 6 homolog (S. cerevisiae) 11 D2 D5 ...
BG077054 C Ncbp2 Nuclear cap binding protein subunit 2, 20 kDa 16 D2 ... ...
BG062969 C Hnrpdl Heterogeneous nuclear ribonucleoprotein D-like 5 D2 ... ...
576635 C Vcam1 Vascular cell adhesion molecule 1 3 D2 ... ...
402711 C Crybb1 Crystallin, beta B1 5 ... ... D7
BG080965 C Prkcbp1 Protein kinase C binding protein 1 2 ... ... D7
BG074422 C Itgb1 Integrin beta 1 (fibronectin receptor beta) 8 ... D5 ...
BG084605 C Bpgm 2,3-bisphosphoglycerate mutase 6 D2 ... ...
BG078316 C Sfxn1 Sideroflexin 1 13 ... ... D7
BG076061 C Lyar Ly1 antibody reactive clone 5 ... ... D7
BG077320 C Mrps10 Mitochondrial ribosomal protein S10 17 D2 ... ...
BG077670 C Gnai2 Guanine nucleotide binding protein, alpha inhibiting 2 9 D2 ... D7
406838 C Foxo3a Forkhead box O3a 10 ... ... D7
BG072299 C Ramp2 Receptor (calcitonin) activity modifying protein 2 19 ... ... D7
1224916 C Atxn7 Ataxin 7 14 D2 ... ...
1395654 C Batf Basic leucine zipper transcription factor, ATF-like 12 D2 D5 ...
BG087349 C Aldh1b1 Aldehyde dehydrogenase 1 family, member B1 4 D2 ... ...
596637 C Stab2 Stabilin 2 10 D2 ... ...
596064 C Cd5 CD5 antigen 19 D2 ... ...
573880 C Nfyc Nuclear transcription factor-Y gamma 4 D2 ... ...
1226020 C Unknown Unknown ... D2 ... D7
400157 C Uqcrq Ubiquinol-cytochrome c reductase binding protein 11 ... ... D7
BG086406 C Agtr2 Angiotensin II receptor, type 2 X ... ... D7
582804 C Cys1 Cystin 1 12 ... D5 ...
576480 C Igf2bp3 Insulin-like growth factor 2 mRNA binding protein 3 6 D2 D5 ...
464586 C Srr Serine racemase 11 D2 ... ...
575610 C 2700085E05Rik RIKEN cDNA 2700085E05 gene 11 D2 ... ...
575040 C Sel1h Sel1 (suppressor of lin-12) 1 homolog (C. elegans) 12 D2 ... ...
BG087165 C Herc4 Hect domain and RLD 4 10 D2 ... D7
BG073254 C Rbmxrt RNA binding motif protein, X chromosome retrogene 8 D2 ... ...
BG073981 C Gtpbp8 GTP-binding protein 8 (putative) 16 ... D5 D7
573285 C Lrriq2 Leucine-rich repeats and IQ motif containing 2 16 D2 ... ...
372621 C Icam5 Intercellular adhesion molecule 5, telencephalin 9 ... ... D7
1428894 C Ptpns1 Protein tyrosine phosphatase, non-receptor type substrate 1 2 ... ... D7
BG076772 C Gpd2 Glycerol phosphate dehydrogenase 2, mitochondrial 2 ... ... D7BMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
Page 8 of 16
(page number not for citation purposes)
752149 C Stk16 Serine/threonine kinase 16 1 ... D5 D7
573328 C Thrsp Thyroid hormone responsive SPOT14 homolog (Rattus) 7 ... D5 D7
BG087431 C Sec31a SEC31 homolog A (S. cerevisiae) 5 D2 ... ...
BG087401 C Brd7 Bromodomain-containing 7 8 D2 D5 D7
1361813 C Mmachc Methylmalonic aciduria cblC type, with homocystinuria 4 D2 ... ...
BG076501 C Sfrs6 Splicing factor, arginine/serine-rich 6 2 ... ... D7
1243669 C Aldoa Aldolase 1, A isoform 7 ... D5 ...
476643 C Sez6l Seizure related 6 homolog like 5 D2 ... ...
BG075757 C Cd81 CD 81 antigen 7 D2 ... ...
574496 C Usp19 Ubiquitin specific peptidase 19 9 D2 D5f ...
BG065688 C Uba52 Ubiquitin A-52 residue ribosomal protein fusion product 1 8 ... ... D7
BG078688 C Dtnb Dystrobrevin, beta 12 ... ... D7
BG086001 C Sv2a Synaptic vesicle glycoprotein 2 a 3 ... ... D7
BG073641 C Rpl27 Ribosomal protein L27 11 D2 ... ...
BG087402 C Hnrpu Heterogeneous nuclear ribonucleoprotein U 1 ... ... D7
595925 C Sell Selectin, lymphocyte 1 D2 ... ...
1345776 C Rbm14 RNA binding motif protein 14 19 ... ... D7
BG077327 C Gins4 GINS complex subunit 4 (Sld5 homolog) 8 D2 D5 ...
387319 C Zfp346 Zinc finger protein 346 13 D2e ... D7
AW54656
5
C Exosc7 Exosome component 7 9 ... ... D7
BG072456 C Pih1d1 PIH1 domain containing 1 7 ... ... D7
BG074521 C Npm1 Nucleophosmin 1 11 D2 ... ...
BG085278 C Rpl22 Ribosomal protein L22 4 D2e D5 D7
1445843 C Ahcyl1 S-adenosylhomocysteine hydrolase-like 1 3 D2 ... D7
BG087592 C Fbxw7 F-box and WD-40 domain protein 7, archipelago homolog (Drosophila) 3 D2 D5e D7
BG064589 C Atp6v1a1 ATPase, H+ transporting, lysosomal 70 kD, V1 subunit A, isoform 1 16 D2 ... D7
441227 C Abtb1 Ankyrin repeat and BTB (POZ) domain containing 1 6 D2 D5 ...
386911 C Trim29 Tripartite motif protein 29 9 ... ... D7
BG087083 C Serinc3 Serine incorporator 3 2 D2 ... ...
372340 C Myod1 Myogenic differentiation 1 7 D2 ... ...
BG081915 C Ube3a Ubiquitin protein ligase E3A 7 D2 D5 ...
573124 C Mrrf Mitochondrial ribosome recycling factor 2 D2 D5 ...
573230 C 4930455C21Rik RIKEN cDNA 4930455C21 gene 16 ... ... D7
1243507 C Unknown Unknown ... D2 D5 D7
BG065706 C Rabl3 RAB, member of RAS oncogene family-like 3 16 ... ... D7
BG078879 C Cox4i1 Cytochrome c oxidase, subunit IVa 8 D2 ... ...
BG088493 C Ptplad1 Protein tyrosine phosphatase-like A domain containing 1 9 ... ... D7
1378435 C Acad8 acyl-Coenzyme A dehydrogenase family, member 8 9 D2 ... ...
1429286 C 1600002K03Rik RIKEN cDNA 1600002K03 gene 10 ... D5 ...
BG078872 C Pfkfb2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 1 ... D5 ...
420477 C Col13a1 Procollagen, type XIII, alpha 1 10 D2 ... ...
402631 C Crebl1 cAMP responsive element binding protein-like 1 17 ... D5 ...
1445700 C 4930506M07Rik RIKEN cDNA 4930506M07 gene 19 D2e ... D7
575274 C Nvl Nuclear VCP-like 1 D2 ... D7
574369 C Il4 Interleukin 4 11 D2 D5 D7
BG071511 C Suclg1 Succinate-CoA ligase, GDP-forming, alpha subunit 6 D2 ... D7
573178 C Igfbp7 Insulin-like growth factor binding protein 7 5 ... D5 ...
574126 C Dnaja3 DnaJ (Hsp40) homolog, subfamily A, member 3 16 D2 ... D7
1226596 C Fem1c fem-1 homolog c (C.elegans) 18 D2e D5 D7
BG087153 C Bckdha Branched chain ketoacid dehydrogenase E1, alpha polypeptide 7 D2e D5 D7
402019 C Golga7 Golgi autoantigen, golgin subfamily a, 7 8 D2e ... D7
574168 C Prosc Proline synthetase co-transcribed 8 D2e D5 D7
BG073436 C Atp5b ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit 10 D2e D5 D7
574027 C Med19 Mediator of RNA polymerase II transcription, subunit 19 homolog (yeast) 2 D2 D5 ...
1243989 C Mfhas1 Malignant fibrous histiocytoma amplified sequence 1 8 D2 D5 D7
373233 C Itgb5 Integrin beta 5 16 ... ... D7
BG085816 C Spna2 Alpha-spectrin 2, brain 2 ... ... D7
1446130 C 2410166I05Rik RIKEN cDNA 2410166I05 gene 4 D2 ... D7
1263575 C Stard4 StAR-related lipid transfer (START) domain containing 4 18 D2 D5 ...
1852943 C Ankrd17 Gene trap ankyrin repeat 5 ... ... D7
389112 C Palm Paralemmin 10 ... ... D7
619816 C Smad5 MAD homolog 5 (Drosophila) 13 ... ... D7
641790 C BC023814 cDNA sequence BC023814 3 ... ... D7
1329743 C S3–12 Plasma membrane associated protein, S3–12 17 ... ... D7
653795 C Il4ra Interleukin 4 receptor, alpha 7 D2 ... D7
640435 C Igsf3 Immunoglobulin superfamily, member 3 3 ... ... D7
387990 C 0610040D20Rik RIKEN cDNA 0610040D20 gene 9 D2 D5 ...
BG075962 C Peci Peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase 13 D2 ... ...
BG086412 C Rpl31 Ribosomal protein L31 1 D2 ... ...
BG075914 C Rps9 Ribosomal protein S9 7 D2 ... ...
639852 CB s g B a s i g i n 10 D2 ... ...
Table 2: CM-specific genes obtained by use of the Welch t test and a Bonferroni correction (Continued)BMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
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573106 C Slc25a1 Solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 16 D2 ... D7
574123 C Suds3 Suppressor of defective silencing 3 homolog (S. cerevisiae) 5 D2 ... ...
BG088819 C 1810043G02Rik RIKEN cDNA 1810043G02 gene 10 D2 ... ...
BG088858 C 1810044A24Rik RIKEN cDNA 1810044A24 gene 15 D2 D5 D7
BG078275 C C230096C10Rik RIKEN cDNA C230096C10 gene 4 D2 ... D7
573120 C 2310035K24Rik RIKEN cDNA 2310035K24 gene 2 D2 D5 ...
BG076791 C Eef1d Eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein) 15 D2 ... ...
BG087946 C Ubtf Transcription factor UBF 11 D2 D5f D7
372316 C Ly6h Lymphocyte antigen 6 complex, locus H 15 D2 ... D7
1243611 C Tmem23 Transmembrane protein 23 19 D2 D5 D7
574299 C 2700059D21Rik RIKEN cDNA 2700059D21 gene 4 ... D5 D7
BG064820 C Sae1 SUMO1 activating enzyme subunit 1 7 D2 ... ...
BG071827 C Ppm1b Protein phosphatase 1B, magnesium dependent, beta isoform 17 D2 D5f ...
BG086606 C Txndc12 Thioredoxin domain containing 12 (endoplasmic reticulum) 4 D2 ... ...
BG085962 C Gsn Gelsolin 2 D2 ... ...
575308 C Dus3l Dihydrouridine synthase 3-like (S. cerevisiae) 17 ... ... D7
573228 C Fyco1 FYVE and coiled-coil domain containing 1 9 D2 D5 ...
BG081532 C Sfpq Splicing factor proline/glutamine rich (polypyrimidine tract binding protein associated) 4 D2 D5f D7f
BG072614 C Rps16 Ribosomal protein S16 7 D2 ... ...
BG078928 C Stmn3 Stathmin-like 3 2 ... ... D7
1226306 C Cd274 CD274 antigen 19 D2 D5 ...
AW54462
8
C Itgb1 Integrin beta 1 (fibronectin receptor beta) 8 D2 ... D7
BG087322 C Rps6ka2 Ribosomal protein S6 kinase, 90 kD, polypeptide 2 17 D2 D5 ...
641964 C Cd4 CD4 antigen 6D 2 D 5 f ...
BG071505 C Slc28a3 Solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 13 D2 D5 ...
BG088775 C Znhit3 Zinc finger, HIT type 3 11 D2 D5 ...
BG069977 C Pmm1 Phosphomannomutase 1 15 D2 D5 ...
574022 E 1200015M12Rik RIKEN cDNA 1200015M12 gene 3 D2 ... ...
BG086286 E Cirbp Cold inducible RNA binding protein 10 D2 ... ...
598493 E Ifit3 Interferon-induced protein with tetratricopeptide repeats 3 19 D2 D5 ...
617022 "" " "" " "
1329893 E 2600010E01Rik RIKEN cDNA 2600010E01 gene 2 ... ... D7
BG076479 E Ctla2a Cytotoxic T lymphocyte-associated protein 2 alpha 13 ... D5f D7
BG088327 E Sf3b1 Splicing factor 3b, subunit 1, 155 kDa 1 ... D5 ...
BG076355 E Stat3 Signal transducer and activator of transcription 3 11 D2 ... ...
643048 E Gbp6 Guanylate binding protein 6 3 ... D5 ...
638199 E H2-T22 Histocompatibility 2, T region locus 22 17 D2 D5f ...
638232 E Jundm2 Jun dimerization protein 2 12 D2 D5 ...
1394984 E Rps14 Ribosomal protein S14 18 ... ... D7
a Clone ID or GenBank accession no.
b The genes Il4ra and Ifit3 were duplicates (the same clone for the gene Il4ra and two different clones for the gene Ifit3). Thus, there were 177 genes identified.
c Chromosomal localization.
d The days for which the Welch t test was significant (<0.0001) after Bonferroni correction are mentioned.
e Significant difference was observed only between BALB/c and C57BL/6.
f Significant difference was observed only between BALB/c and CBA/J.
Table 2: CM-specific genes obtained by use of the Welch t test and a Bonferroni correction (Continued)
fied a number of genes differentially regulated between
CM-R and CM-S mice. The 327 most differentially
expressed genes identified by the SAM analysis allowed
the complete discrimination between CM-R and CM-S
mice according to the time of infection. The same result
was obtained with the subset of 177 genes identified by
the Welch t test (data not shown). This further confirms
our previous study that investigated gene expression at the
time of CM onset [8].
EASE analysis of either the 327 genes or the 177 genes
revealed that some of the most represented biological
process categories were related to the "defense response",
such as the "response to parasite" or the "inflammatory
response" terms. This was further supported by the results
of the KEGG pathway analysis. In addition, genes were
found to be involved in KEGG pathways related to metab-
olism, such as "oxidative phosphorylation", "glycolysis/
gluconeogenesis", or "tryptophan metabolism". The anal-
ysis of functional annotation also revealed GO terms and
KEGG pathways related to brain, such as the "axon guid-
ance" and the "neurodegenerative disorders" KEGG path-
ways.
Overall, the analysis of functional annotation is consist-
ent with the view that mouse CM is characterized among
others by the deregulation of both immune response and
glucose metabolism [11,12]. This leads to an abnormal
increase in the inflammatory response and to hypoglyc-
emia and acidosis in CM-S mice [11,12]. In addition, our
data provide evidence of an intrinsic deficiency in oxida-
tive phosphorylation, and the functional annotations
related to brain disease suggest the role of genes expressed
by brain cells in resistance or susceptibility to CM. Thus,BMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
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despite a number of genes identified by our microarray
analysis, which may highlight highly complex interac-
tions between the parasite and the host, several major fea-
tures of the transcriptional profile can be deduced.
First, PbA infection affects the expression of genes
involved in metabolic energy pathways. The expression of
Uqcrq, Cox4i1, Ndufb8, Atp6v1g2 and Atp5b involved in
oxidative phosphorylation was upregulated in CM-R mice
on day 2 post-infection [see Additional file 2], suggesting
that cerebral oxidative metabolism may be stimulated by
PbA infection in CM-R mice. In contrast, these genes were
downregulated in C57BL/6 mice on day 2 post-infection
and in CBA/J mice on day 7 post-infection, while only
Ndufb8 was downregulated in CBA/J mice on day 2 post-
infection. These transcriptional changes were associated
with CM. A similar pattern was observed for Hmgcs1
involved in ketone metabolism. In the same way, lower
NAD+/NADH levels and decreased mitochondrial func-
tion have been observed in CM-S mice by others [12,13].
These observations may be related to hypoxia and
hypoglycemia, which reflect the low level of metabolic
energy substrates. Alternatively, our data are consistent
with the "cytopathic hypoxia" hypothesis, which rather
proposes an adequate oxygen supply but an abnormal
oxygen use [14]. Also, the low level of oxidative phospho-
rylation gene expression and ketone bodies pathway
genes that we detected in the brain of CM-S mice suggests
that cerebral oxidative metabolism may be inhibited even
without oxygen delivery being impaired.
This metabolic disturbance also leads to lactate produc-
tion and acidosis. In addition, this leads to an accumula-
tion of ADP, which favors platelet aggregation [15].
Interestingly, platelet aggregation is known to be stimu-
lated by PAF acether and inhibited by AMPc, the expres-
sion of which is inhibited by LIS1 (PAFAH1B1) and
PDE4B, respectively [16,17]. Overall, the lower expression
of Pafah1b1 in CM-S mice compared to CM-R mice [8],
the higher expression of Pde4b in CM-S mice compared to
CM-R mice, and the metabolic disturbance leading to an
accumulation of ADP may participate in the platelet
aggregation process in the cerebral microvasculature of
CM-S mice.
Second, it is likely that the inflammatory response plays a
major role in CM pathogenesis. In particular, a surge of
IFNγ production at 3 to 4 days p.i. was demonstrated to be
essential for murine CM, and this may be due to the
absence of regulation in IFNγ pathways at early stages in
PbA infection [18-20]. IFNγ is a proinflammatory
cytokine typically produced by Th1 lymphocytes, and it is
thought that the Th2 response protects from CM [11]. In
this way, our microarray analysis showed that IL4 and
IL4R were over-expressed in CM-R mice from day 2. Sim-
ilarly, Dnaja3, Foxo3a, and Ptpns1 that inhibit the activity
of NF-kB [21-23] had lower expression levels in CM-S
mice than in CM-R mice, while Nfkbia, a marker of the NF-
kB signalling pathway involved in inflammation [24], was
over-expressed in CM-S mice. In addition, C1qa and Pde4b
Genes differentially expressed between CM-R and CM-S  mice on days 2, 5, and 7 Figure 6
Genes differentially expressed between CM-R and 
CM-S mice on days 2, 5, and 7. The number of genes up-
regulated in CM-S mice compared to CM-R mice (A), and 
the number of genes up-regulated in CM-R mice compared 
to CM-S mice (B) are shown.
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Table 3: Functional KEGG annotation of genes associated with 
resistance or susceptibility to CM
KEGG pathwaysa Percentage of 
significant CM genesb
Ribosome 13.3
Cell adhesion molecules (CAMs) 10.0
Antigen processing and presentation 8.3
Oxidative phosphorylation 6.7
Hematopoietic cell lineage 6.7
Leukocyte transendothelial migration 6.7
ECM-receptor interaction 6.7
Cytokine-cytokine receptor interaction 5.0
Glycolysis/Gluconeogenesis 5.0
Fructose and mannose metabolism 5.0
Regulation of actin cytoskeleton 5.0
T cell receptor signaling pathway 5.0
Jak-STAT signalling pathway 5.0
Axon guidance 5.0
Valine, leucine and isoleucine degradation 5.0
Focal adhesion 5.0
Tight junction 5.0
MAPK signaling pathway 3.3
B cell receptor signaling pathway 3.3
Tryptophan metabolism 3.3
Propanoate metabolism 3.3
Butanoate metabolism 3.3
Bile acid biosynthesis 3.3
Fatty acid metabolism 3.3
Adipocytokine signaling pathway 3.3
Neuroactive ligand-receptor interaction 3.3
Neurodegenerative Disorders 3.3
a Only the KEGG pathways that contained at least two genes were 
represented.
b Of the 177 significant CM genes, 60 genes were annotated.BMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
Page 11 of 16
(page number not for citation purposes)
that are involved in the inflammatory response [17,25]
were found to be over-expressed in CM-S mice compared
to CM-R mice. S100a10 that inhibits the activity of phos-
pholipase A2 [26], and Bcl6 that inhibits the production
of MIP-alpha and IP-10 [27] were under-expressed in CM-
S mice compared to CM-R mice. Blood cells are known to
be involved in the inflammatory response due to malarial
infection. Indeed, CD4+ and CD8+ T lymphocytes, plate-
lets, monocytes have been shown to cooperate in the cer-
ebral microvasculature, and this causes inflammation,
endothelial cell damage, and hemorrhages [9,20,28-30].
In addition, Gzmb, whose expression was up-regulated in
CM-S mice [8], encodes granzyme B in cytotoxic T lym-
phocytes, and is thought to be involved in the breakdown
of the blood-brain barrier [31]. The influence of immune
responses on the blood-brain barrier may be partly
reflected by changes in expression of genes involved in
either cytoskeletal and tight-junction pathways or cell
adhesion pathways in CM-S mice.
It has been also suggested that glial cells actively partici-
pate in the local inflammatory response caused by malar-
ial infection [32]. In this way, glial cells that have been
shown to be activated on day 3 post-infection by PbA can
produce C1q components [32,33]. The NF-kB signalling
pathway has been demonstrated in these cells [34]. Inter-
estingly, Cd200 that is implicated in the control of the
activation of glial cells was strongly under-expressed in
the CBA/J CM-S mice [35]. Besides, the expression of IL4
and IL4R was shown to be higher in CM-R mice than in
CM-S mice. Since IL-4 induces apoptosis in activated glial
cells that express IL-4R [36], IL-4 may contribute to the
down-regulation of brain inflammation in CM-R mice.
Third, genes involved in the neuroprotection/neurotoxic-
ity balance and/or in neurogenesis may protect the host
against CM. This hypothesis is based on changes in tryp-
tophan metabolism caused by PbA infection. Sanni et al
(1998) showed an increase of the activity of indoleamine
2,3-dioxygenase whose expression is induced by TNF and
IFNγ [37]. This leads to an increase of the ratio quinolinic
acid/kynurenic acid, and to neuro-excitotoxic damage
associated with CM. In humans, high levels of quinolinic
acid have been associated with CM [38]. Interestingly,
genes involved in tryptophan metabolism, such as Ube3a,
Prnt3, and Aldh1b1, were differentially regulated between
CM-R and CM-S mice. The expression of these genes was
enhanced by infection in CM-R mice. In addition, genes
having a neuroprotective role, such Agtr2, Bag1, Csnk1a1
and Reln [39-42], were shown to be over-expressed in CM-
R mice compared to CM-S mice. Indeed, Rtn3 and Creb1
that are markers of neuronal survival [43,44], were also
over-expressed in CM-R mice. Besides, Reln  and  Dab1,
which were over-expressed in CM-R mice, are known to be
involved in neurogenesis [45,46]. Similarly, Pafah1b1
whose expression was associated with resistance to CM [8]
is involved in the Reln pathway [46]. This suggests that
CM-S mice are deficient in neurogenesis, and that they
cannot repair neuronal damages. In contrast, CM-R mice
might be able to repair such damage (Figure 7).
So far, little research has been conducted on the issue of
neuroprotective responses in CM. Interestingly, the Reln
pathway that inhibits the phosphorylation of the protein
Tau has been recently proposed as a protective mecha-
nism against Alzheimer'disease [47]. In addition,
decreased ribosomal RNA levels and decreased rates for
protein synthesis have been recently described in Alzhe-
imer'disease [48], while we showed the down-regulation
of several genes encoding ribosomal proteins in CM-S
mice. In the same way, Medana et al (2002) detected β-
amyloid precursor protein in humans with CM [49], and
we report here the β-amyloid protein in brains of CM-S
mice but not in CM-R mice. This result is consistent with
the down-regulation of Arc, Itm2b, Bsg, Rtn3, and Il4 in
CM-S mice, and with the up-regulation of Pde4b in CM-S
mice. Indeed, Itm2b, Bsg, Rtn3, and Il4 inhibit the produc-
tion of the β-amyloid protein [50-53]. Besides, the β-amy-
loid protein inhibits the expression of Arc, while it
increases the expression of Pde4b [25,54]. These observa-
tions suggest that cerebral malaria and Alzheimer'disease
share some common mechanisms of pathogenesis.
Table 4: Protein expression in brain of CM-R and CM-S mice upon malaria infection
d0/d2 D5 d7
BALB/c CBA/J C57BL/6 BALB/c CBA/J C57BL/6 BALB/c CBA/J C57BL/6
R e e l i n --- + + -- + + + --
β- A m y l o i d ----+ +- + + + +
n = 3, at least 25 brain fields analysed per mouse.
-: no positive vessel
+: from 1 to 5 postive areas/vessels per field
++: from 6 to 10 postive areas/vessels per field
+++: > 10 positive areas/vessels per field
d0/d2: results were similar for both day 0 and day 2.BMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
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Conclusion
In this study, we have confirmed that gene-expression
profiling discriminates between CM-R and CM-S mice,
and we have identified genes whose expression showed
consistent differential expression between CM-R and CM-
S mice at early and late stages of infection. The analysis of
gene functional annotation reveals several major features.
First, it indicated that brain metabolic energy metabolism
was early and deeply disturbed in CM-S mice, suggesting
that high lactate production may be due rather to meta-
bolic disturbance than to deficient oxygen supply. Sec-
ond, the influence of inflammatory response on CM was
also clearly detected, and our data are consistent with an
active role of microglial cells in local inflammation. Third,
the outcome of infection may critically depend on either
cerebral tissue protective responses or brain repair capac-
ity. Overall, our microarray analysis may give a global
overview of critical events occurring in CM-S mice com-
pared to CM-R mice. Searching for polymorphisms that
alter the expression of genes identified should help in
determining the genetic control of cerebral malaria. This
analysis also revealed some promising areas for explora-
tion that may both provide new insight into the key events
that govern CM pathogenesis and the development of
therapeutic strategies. In particular, novel neuroprotective
therapies may be proposed as adjuncts to anti-malarial
therapy.
Methods
Mouse strains and phenotyping
Six to 8 weeks old BALB/c (CM-R strain), C57BL/6J and
CBA/J (CM-S strains) female, were obtained from IFFA
CREDO (Ch. River Lab, France) and kept in our facilities.
Three mice from each strain were not infected, and 22
BALB/c, 17 C57BL/6J, and 15 CBA/J were infected by i.p.
injection of 106 PbA parasitized erythrocytes. The frozen
stabilates were obtained with an uncloned line, and were
prepared from CBA/J day 7-infected mice [30]. The para-
site was conserved as stabilates of 107 parasitized erythro-
cytes stored in liquid nitrogen in Alsever's solution
containing 10% glycerol. Parasitemia was monitored
daily by blood smear. No difference was observed
between mouse strains. Parasitemia was 0.8%±0.9,
4.5%±2.2, and 8.7%±5.3 on days 2, 5, and 7 post-infec-
tion, respectively. The CM-S mice developed a neurologi-
cal syndrome (mono-, hemi-, para-, or tetraplegia, ataxia,
deviation of the head, and convulsions), which occurred
6 to 7 days after parasite inoculation with a cumulative
mortality of 100%. The CM-R mice did not present neuro-
logic lesions and died during the 3rd or the 4th week of
infection, with severe anaemia and hyperparasitemia [9].
The parasitemia of CM-R mice was 16.6%±8.9 and
62.8%±25.7 on days 9 and 15, respectively.
Schematic diagram showing the possible effects of the reelin  pathway in protection from CM Figure 7
Schematic diagram showing the possible effects of 
the reelin pathway in protection from CM. Reelin 
(RELN) is an extracellular matrix serine protease expressed 
in some neurons, such as GABAergic interneurons, which 
inhibit excitotoxic neurotransmission [45]. RELN that is 
secreted into the extracellular space acts by paracrine and 
autocrine mechanisms. RELN interacts with very low-density 
lipoprotein receptors (VLDLR) and apolipoprotein E type 2 
receptors (ApoER2) leading to tyrosine phosphorylation of 
the adaptor protein Disabled-1 (DAB1) by the SRC family 
kinases (SRC) [42]. DAB1 activation, in turn, activates PI3K/
Akt signalling, which has been implicated in neuronal migra-
tion during development and adulthood. In addition, phos-
phorylated DAB1 interacts with LIS1, a protein encoded by 
Pafah1b1, which associates with microtubules and modulates 
neuronal migration [46]. LIS1 may be required for regulating 
crucial steps of reelin-dependent neuronal positioning. In 
parallel, phosphorylated DAB1 inhibits glycogen synthase 
kinase 3β (GSK3β), a kinase known to phosphorylate Tau 
protein at multiple sites. Therefore, the activation of RELN 
pathway diminishes the level of hyperphosphorylated Tau 
protein, which is a biomarker of brain injury. In particular, 
hyperphosphorylated Tau protein is a component of the neu-
rofibrillary tangles involved in Alzheimer's disease. Reln, Dab1 
and Pafah1b1 were shown to be over-expressed in CM-R 
mice compared to CM-S mice. The activation of RELN signal-
ling may inhibit excitotoxic neurotransmission and Tau phos-
phorylation, and may activate neurogenesis in CM-R mice. 
This may lead to diminished brain injury and to increased 
brain injury repair. Solid arrows represent influences on the 
activity of proteins or physiological mechanisms. Dashed 
arrows represent impaired effects on the activity of proteins 
or physiological mechanisms. Negative signs indicate inhibi-
tion, and positive signs indicate activation.
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Organ sampling
Brains were taken from CM-R and CM-S mice before and
after infection. Brains from three uninfected mice were
taken for each strain. Three, 4, and 6 CBA/J were analyzed
on days 2, 5, and 7 post-infection, respectively, while 4, 4,
and 9 C57BL/6 were analyzed on days 2, 5, and 7 post-
infection, respectively. Brains from 3, 4, 5, 5, and 5 BALB/
c mice were taken on days 2, 5, 7, 9 and 15 post-infection.
Brains were completely removed and were cut into two
parts: one part was frozen in RNALater (Qiagen, TM) until
RNA analysis, and the other part was embedded in Tissue
Tek (Leica), snap frozen in liquid nitrogen, and kept at -
80°C until histopathological analysis of cryosections.
Immunochemistry
For immunostaining, frozen sections were incubated for
45 minutes with primary monoclonal antibodies directed
against murine Reelin and β-Amyloid peptide (Santa
Cruz, Tebu Bio) after saturation with appropriate serum.
After washing, sections were incubated for 45 minutes
with biotinylated polyclonal antibodies, followed by the
addition of HRPO-avidin (anti-rat or anti-hamster ABC
kits; Vector, Peterborough, England). Color reaction was
obtained by the addition of Novared (AbCys). Slides were
counterstained with Mayer's hematoxylin before perma-
nent mounting with Entellan (Merck, Brussels, Belgium).
Slides were pictured at 200 magnification using an Eclipse
800 microscope (Nikon, Champignysur- Marne, France)
and a digital camera; labelling was then analyzed by quan-
titative digitalized image analysis using Lucia software
(Nikon). At least 3 brains were sampled for each time
point and each mouse strain and image analysis was per-
formed on an average of 25 microphotographs per mouse.
RNA isolation and cDNA microarray hybridizations
Total RNA from brains was extracted using TRIzol reagent
(Gibco-BRL, Life Technologies). The quality of RNA was
confirmed on a formaldehyde agarose gel, and the con-
centration of RNA was determined by reading absorbance
at 260/280 nm. RNA from 2 CBA/J mice had an inade-
quate quality, and was not further processed. Each mRNA
sample extracted from an individual brain was run on a
single microarray. In addition, three samples were run on
several microarrays, and were considered as technical rep-
licates: samples from CBA/J, C57BL/6, and BALB/c mice
were run on 5, 2, and 2 microarrays, respectively. All
microarray procedures were done at our microarray core
facility [55]. cDNA microarrays were designed and pre-
pared as described [56]. Briefly, the microarrays used in
this study were composed of 8388 sequences. The follow-
ing cDNA libraries were used: the NIA Mouse 15 K cDNA
clone set, 2NbMT (thymus), NbMLN (lymph node), and
3NbMS (spleen). Detailed descriptions of these cDNA
libraries are available at the UniGene database website
(2NbMT: Lib.544, 3NbMS: Lib.553, NbMLN: Lib.567,
NIA 15 K: Lib.8622) [57]. PCR amplification was per-
formed as previously described [56], and PCR products
were spotted onto nylon membranes (Hybond-N+, Amer-
sham) with a MicroGrid II arrayer (Affymetrix, Santa
Clara, CA). About 10% of the genes included in this clone
set are represented by two or more different cDNA clones,
providing internal controls to assess the reproducibility of
gene expression measurements. Microarrays were hybrid-
ized with 33P-labelled probes, first with an oligonucle-
otide sequence common to all spotted PCR products (5'-
TCACACAGGAAACAGCTATGAC-3'), then after stripping,
with complex probes made from 5 µg of retrotranscribed
total RNA. Probe preparations, hybridizations and washes
were carried out as described previously [56]. After 48 h
hybridization, arrays were scanned with a FUJI BAS5000
machine at 25 µm resolution. Hybridization signals were
quantified using ArrayGauge software (Fuji Ltd, Tokyo,
Japan).
Microarray data analysis
All images were carefully inspected, and spots with over-
estimated intensities due to neighborhood effects were
manually excluded. The data were filtered such that only
spots with intensities that were two times greater than the
median background in either microarray were used in the
analysis, and the signal intensities were then corrected to
take into account the amount of spotted DNA and the var-
iability of experimental conditions, as described [58]. Of
the 8388 spotted clones, we selected the clones that had
detectable expression levels in at least 80% of the experi-
ments (n = 2012). Unsupervised hierarchical clustering
investigated relationships between samples and relation-
ships between genes. It was applied to data log-trans-
formed and median-centred using the Cluster and
TreeView programs (average linkage clustering using Pear-
son's correlation as similarity metric) [59].
Microarray data were statistically analyzed using the TIGR
MeV (MultiExperiment Viewer) v3.1 software [60]. Figure
1 shows an outline of data analysis. A one-way ANOVA
and SAM (Significant Analysis of Microarrays) procedures
were applied to look for time-, strain-, and CM-R/CM-S-
specific variation in gene expression in the full data set.
One-way ANOVA and Welch t-statistics were used to ana-
lyze gene expression changes upon infection for each
mouse strain. The values on days 2, 5, 7, 9 and 15 post-
infection were compared to values on day 0 before infec-
tion. To search for gene expression changes associated
with CM, a multi-class SAM procedure and a Welch t test
were performed on the log2 ratios of infected vs unin-
fected samples. For each gene, the level of gene expression
in each sample taken from an infected mouse was divided
by the median of gene expression levels in samples taken
from three uninfected mice. This calculation was done forBMC Genomics 2007, 8:452 http://www.biomedcentral.com/1471-2164/8/452
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each mouse strain. Multiple test corrections were per-
formed [61].
The Expression Analysis Systematic Explorer (EASE) was
used to search for common biological themes within gene
lists generated by our microarray analysis [62]. EASE
assigns identified genes to Gene Ontology (GO) terms,
and tests whether specific biological pathways were over-
represented within specific gene clusters. A score based on
Fisher Exact test reports the probability that the prevalence
of a particular theme within a cluster is due to chance
alone given the prevalence of that theme in the popula-
tion of all genes under study. In addition, we checked
whether the genes were included in a KEGG pathway [63].
All data are MIAME compliant and have been loaded into
ArrayExpress database [64]. The ArrayExpress accession
number of this experiment is E-MEXP-1018.
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